Logo

CLGN

CollPlant Biotechnologies Ltd.

CLGN

CollPlant Biotechnologies Ltd. • NASDAQ
$2.19 ▼ -1.89% (-0.04)
Market Cap $25.91 M
52w High $4.98
52w Low $1.31
Dividend Yield 0%
P/E -1.94
Volume 13.45K
Outstanding Shares 11.84M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $179K ▼ $2.942M ▼ $-3.347M ▼ -1.87K% ▼ $-0.28 ▼ $-2.949M ▼
Q1-2025 $2.055M ▲ $3.515M ▼ $-1.452M ▲ -70.657% ▲ $-0.13 ▲ $-1.404M ▲
Q4-2024 $164K ▲ $3.866M ▼ $-3.878M ▲ -2.365K% ▲ $-0.34 ▲ $-3.732M ▲
Q3-2024 $4K ▼ $4.274M ▲ $-4.326M ▼ -108.15K% ▼ $-0.38 ▼ $-4.287M ▼
Q2-2024 $249K $4.119M $-4.21M -1.691K% $-0.37 $-4.145M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $11.707M ▲ $17.437M ▲ $4.932M ▲ $12.505M ▲
Q1-2025 $10.735M ▼ $17.208M ▼ $4.811M ▼ $12.397M ▼
Q4-2024 $11.909M ▼ $18.71M ▼ $5.245M ▼ $13.465M ▼
Q3-2024 $15.371M ▼ $22.442M ▼ $5.524M ▼ $16.918M ▼
Q2-2024 $18.92M $26.566M $5.837M $20.729M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-3.347M ▼ $-2.457M ▼ $-3.053K ▲ $3.117M ▲ $727K ▲ $-2.46M ▼
Q1-2025 $-1.452M ▲ $-1.167M ▲ $-8K ▲ $0 $-1.174M ▲ $-1.176M ▲
Q4-2024 $-3.878M ▲ $-3.464M ▼ $-58K ▲ $0 $-3.462M ▲ $-3.523M ▲
Q3-2024 $-4.326M ▼ $-3.448M ▲ $-140K ▲ $0 $-3.549M ▲ $-3.588M ▲
Q2-2024 $-4.21M $-3.928M $-259K $0 $-4.305M $-4.13M

Five-Year Company Overview

Income Statement

Income Statement CollPlant is still very much a development-stage company: revenues are tiny and inconsistent, while expenses are steady, leading to ongoing losses each year. The company briefly broke even a few years ago but has since returned to more noticeable losses as it continues to invest in its pipeline. This pattern is typical for early-stage biotech firms that are focused on research, partnerships, and trials rather than commercial scale sales. The key question for the income statement is whether future product launches and milestone payments can eventually turn these losses into a more sustainable revenue base.

Balance Sheet

Balance Sheet The balance sheet is small and lean, with total assets and shareholder equity both modest and trending down in the most recent year. Cash once made up the bulk of assets, but the cash balance has declined, which is consistent with a company funding operations from its reserves. On the positive side, there is no financial debt, so CollPlant is not burdened by interest payments or large near-term repayments. The trade-off is that the company’s financial cushion is limited, making the timing of future funding, partnerships, or milestones particularly important.

Cash Flow

Cash Flow Cash flow from operations has been slightly negative in most years, reflecting steady cash burn to fund research and development, staff, and overhead. Free cash flow looks similar because the company spends very little on physical capital, so almost all cash usage is operating in nature rather than big equipment or facilities. This pattern suggests a controlled but persistent cash drain: not extreme, but meaningful for a company with a small cash base. Over time, CollPlant will likely need either growing partner payments, product revenues, or new financing to support continued development at its current pace.

Competitive Edge

Competitive Edge CollPlant’s competitive strength rests on its proprietary plant-based human collagen platform, which addresses safety, purity, and scalability concerns associated with animal- or cadaver-derived collagen. Strong patent protection, a complex and hard-to-copy production process, and early partnerships with large industry players give it a real, if still emerging, moat. The company is positioned in attractive niches—medical aesthetics, 3D bioprinting, and regenerative implants—where differentiation and intellectual property matter more than size. The main competitive risk is that larger, better-funded rivals or alternative technologies could move quickly if CollPlant’s programs stumble or are slow to reach market.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of CollPlant’s story. Its platform enables a broad pipeline: bio-inks for 3D bioprinting, regenerative dermal fillers with a major partner, photocurable fillers, and regenerative breast implants, plus some already commercial wound and tendon products. Most of the value drivers are still in preclinical or clinical stages, which means scientific, regulatory, and execution risk remains high, but also that much of the potential is still ahead rather than already realized. The company’s strategy leans heavily on turning its unique collagen technology into multiple product lines and collaborations, rather than relying on a single “winner.”

Summary

CollPlant is a small, research-driven biotech focused on a distinctive plant-based human collagen technology, with very limited current revenue and ongoing operating losses. Its balance sheet is debt-free but also relatively thin, and cash has been trending downward as the company funds development. The long-term appeal lies in its differentiated technology, strong intellectual property, and partnerships in fast-growing areas like medical aesthetics and 3D bioprinting. However, the investment case is highly dependent on successful clinical progress, regulatory approvals, commercialization execution, and access to funding before meaningful, recurring revenues are established.

NEWS

November 26, 2025 · 7:30 AM UTC

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Read more

November 18, 2025 · 7:00 AM UTC

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

Read more

October 27, 2025 · 7:01 AM UTC

CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

Read more

October 20, 2025 · 7:00 AM UTC

CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology

Read more

October 16, 2025 · 7:00 AM UTC

First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

Read more